THE ARISING · Longevity & Healthspan
mRNA-Engineered Immune Cell Therapy Shows Early Signal in End-Stage Liver Disease
For people with end-stage liver disease, the options are narrow: manage the illness and wait, or hope for a transplant. A therapy built from a patient's own immune cells has now posted early results that point in a hopeful direction.
Resolution Therapeutics announced six-month interim results from its Phase I/II EMERALD trial of RTX001. The therapy is an autologous engineered regenerative macrophage therapy. In plain terms, it uses the patient's own macrophages, a type of immune cell, and gives them mRNA that carries instructions for two proteins, IL-10 and MMP-9. That is the company's description of the product.
The report says the analysis compared the first nine of 15 treated patients with 21 standard-of-care patients from an external control group called OPAL. The measure was a combination of death, liver transplant or hepatic decompensation, which is a worsening of the liver's ability to function. It occurred in 2 of 9 treated patients versus 8 of 21 controls. The company calls that a 42 percent relative risk reduction. The comparison group was not randomized, and the numbers are very small.
Transplant or death alone occurred in 11 percent of RTX001-treated patients versus 19 percent in the OPAL group, according to the report.
On safety, the company reports RTX001 was well tolerated, with no infusion-related serious adverse reactions and no severe adverse events related to treatment. The company also reports that biomarker analyses showed reductions in inflammatory pathway activity and in markers of fibrogenesis, the process that builds scar tissue in the liver.
The company scheduled the late-breaking presentation for November 8 at AASLD 2026. EMERALD has finished enrollment, with 15 patients dosed. Its primary analysis is planned for 2028.
Resolution plans a pre-IND meeting with the U.S. Food and Drug Administration in December 2026, and says it intends to advance RTX001 toward a planned U.S. pivotal trial. The next thing to watch is the outcome of that FDA meeting and whether the pivotal trial design follows.
These small, nonrandomized interim comparisons cannot establish a treatment effect or broad safety. The findings remain company-reported rather than an independently reviewed outcome report.